REFERENCES
- 1
Scheuer P J.
Classification of chronic viral hepatitis: a need for reassessment.
J Hepatol.
1991;
13(3)
372-374
- 2
Moschcowitz E.
An acute febrile pleiochromic anemia with hyaline thrombosis of the terminal arterioles
and capillaries; an undescribed disease.
Am J Med.
1952;
13(5)
567-569
- 3
Cuttner J.
Splenectomy, steroids, and dextran 70 in thrombotic thrombocytopenic purpura.
JAMA.
1974;
227(4)
397-402
- 4
Amorosi E L, Karpatkin S.
Antiplatelet treatment of thrombotic thrombocytopenic purpura.
Ann Intern Med.
1977;
86(1)
102-106
- 5
Amorosi E, Ultmann J.
Thrombotic, thrombocytopenic purpura: report of 16 cases and review of the literature.
Medicine (Baltimore).
1966;
45
139-159
- 6
Cuttner J.
Thrombotic thrombocytopenic purpura: a ten-year experience.
Blood.
1980;
56(2)
302-306
- 7
Liang T J, Rehermann B, Seeff L B, Hoofnagle J H.
Pathogenesis, natural history, treatment, and prevention of hepatitis C.
Ann Intern Med.
2000;
132(4)
296-305
- 8
Sangiovanni A, Prati G M, Fasani P et al..
The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort
study of 214 patients.
Hepatology.
2006;
43(6)
1303-1310
- 9
Seeff L B, Buskell-Bales Z, Wright E C et al..
Long-term mortality after transfusion-associated non-A, non-B hepatitis. The National
Heart, Lung, and Blood Institute Study Group.
N Engl J Med.
1992;
327(27)
1906-1911
- 10
Seeff L B, Hollinger F B, Alter H J et al..
Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type
C hepatitis: A National Heart, Lung, and Blood Institute collaborative study.
Hepatology.
2001;
33(2)
455-463
- 11
Tong M J, el-Farra N S, Reikes A R, Co R L.
Clinical outcomes after transfusion-associated hepatitis C.
N Engl J Med.
1995;
332(22)
1463-1466
- 12
Kiyosawa K, Sodeyama T, Tanaka E et al..
Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular
carcinoma: analysis by detection of antibody to hepatitis C virus.
Hepatology.
1990;
12(4 Pt 1)
671-675
- 13
Datz C, Cramp M, Haas T et al..
The natural course of hepatitis C virus infection 18 years after an epidemic outbreak
of non-A, non-B hepatitis in a plasmapheresis centre.
Gut.
1999;
44(4)
563-567
- 14
Barrett S, Goh J, Coughlan B et al..
The natural course of hepatitis C virus infection after 22 years in a unique homogenous
cohort: spontaneous viral clearance and chronic HCV infection.
Gut.
2001;
49(3)
423-430
- 15
Seeff L B, Miller R N, Rabkin C S et al..
45-year follow-up of hepatitis C virus infection in healthy young adults.
Ann Intern Med.
2000;
132(2)
105-111
- 16
Wiese M, Berr F, Lafrenz M, Porst H, Oesen U.
Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in
Germany: a 20-year multicenter study.
Hepatology.
2000;
32(1)
91-96
- 17
Rodger A J, Roberts S, Lanigan A, Bowden S, Brown T, Crofts N.
Assessment of long-term outcomes of community-acquired hepatitis C infection in a
cohort with sera stored from 1971 to 1975.
Hepatology.
2000;
32(3)
582-587
- 18
de Lédinghen V, Trimoulet P, Mannant P R et al..
Outbreak of hepatitis C virus infection during sclerotherapy of varicose veins: long-term
follow-up of 196 patients (4535 patient-years).
J Hepatol.
2007;
46(1)
19-25
- 19
Poynard T, Bedossa P, Opolon P.
Natural history of liver fibrosis progression in patients with chronic hepatitis C.
The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups.
Lancet.
1997;
349(9055)
825-832
- 20
Zarski J P, Mc Hutchison J, Bronowicki J P et al..
Rate of natural disease progression in patients with chronic hepatitis C.
J Hepatol.
2003;
38(3)
307-314
- 21
Hand D.
Statistics and theory of measurements.
J R Stat Soc.
1996;
159
445-492
- 22
Berk P D.
An editor's look-back.
Hepatology.
2006;
43(2, Suppl 1)
S13-S30
- 23
The French METAVIR Cooperative Study Group .
Intraobserver and interobserver variations in liver biopsy interpretation in patients
with chronic hepatitis C.
Hepatology.
1994;
20(1 Pt 1)
15-20
- 24
Westin J, Lagging L M, Wejstål R, Norkrans G, Dhillon A P.
Interobserver study of liver histopathology using the Ishak score in patients with
chronic hepatitis C virus infection.
Liver.
1999;
19(3)
183-187
- 25
Goldin R D, Goldin J G, Burt A D et al..
Intra-observer and inter-observer variation in the histopathological assessment of
chronic viral hepatitis.
J Hepatol.
1996;
25(5)
649-654
- 26
Hourigan L F, Macdonald G A, Purdie D et al..
Fibrosis in chronic hepatitis C correlates significantly with body mass index and
steatosis.
Hepatology.
1999;
29(4)
1215-1219
- 27
Clouston A D, Jonsson J R, Purdie D M et al..
Steatosis and chronic hepatitis C: analysis of fibrosis and stellate cell activation.
J Hepatol.
2001;
34(2)
314-320
- 28
Adinolfi L E, Gambardella M, Andreana A, Tripodi M F, Utili R, Ruggiero G.
Steatosis accelerates the progression of liver damage of chronic hepatitis C patients
and correlates with specific HCV genotype and visceral obesity.
Hepatology.
2001;
33(6)
1358-1364
- 29
Everhart J E, Lok A S, Kim H Y HALT-C Trial Group et al.
Weight-related effects on disease progression in the hepatitis C antiviral long-term
treatment against cirrhosis trial.
Gastroenterology.
2009;
137(2)
549-557
- 30
Kallwitz E R, Layden-Almer J, Dhamija M et al..
Ethnicity and body mass index are associated with hepatitis C presentation and progression.
Clin Gastroenterol Hepatol.
2010;
8(1)
72-78
- 31
Fattovich G, Giustina G, Degos F et al..
Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up
study of 384 patients.
Gastroenterology.
1997;
112(2)
463-472
- 32
Gordon S C, Bayati N, Silverman A L.
Clinical outcome of hepatitis C as a function of mode of transmission.
Hepatology.
1998;
28(2)
562-567
- 33
Bonis P A, Tong M J, Blatt L M, Conrad A, Griffith J L.
A predictive model for the development of hepatocellular carcinoma, liver failure,
or liver transplantation for patients presenting to clinic with chronic hepatitis
C.
Am J Gastroenterol.
1999;
94(6)
1605-1612
- 34
Yano M, Kumada H, Kage M et al..
The long-term pathological evolution of chronic hepatitis C.
Hepatology.
1996;
23(6)
1334-1340
- 35
Marcellin P, Boyer N, Gervais A et al..
Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients
with chronic hepatitis C and sustained response to interferon-alpha therapy.
Ann Intern Med.
1997;
127(10)
875-881
- 36
Reichard O, Glaumann H, Frydén A, Norkrans G, Wejstål R, Weiland O.
Long-term follow-up of chronic hepatitis C patients with sustained virological response
to alpha-interferon.
J Hepatol.
1999;
30(5)
783-787
- 37
Formann E, Steindl-Munda P, Hofer H et al..
Long-term follow-up of chronic hepatitis C patients with sustained virological response
to various forms of interferon-based anti-viral therapy.
Aliment Pharmacol Ther.
2006;
23(4)
507-511
- 38
Shiratori Y, Imazeki F, Moriyama M et al..
Histologic improvement of fibrosis in patients with hepatitis C who have sustained
response to interferon therapy.
Ann Intern Med.
2000;
132(7)
517-524
- 39
Veldt B J, Heathcote E J, Wedemeyer H et al..
Sustained virologic response and clinical outcomes in patients with chronic hepatitis
C and advanced fibrosis.
Ann Intern Med.
2007;
147(10)
677-684
- 40
Maylin S, Martinot-Peignoux M, Moucari R et al..
Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis
C.
Gastroenterology.
2008;
135(3)
821-829
- 41
George S L, Bacon B R, Brunt E M, Mihindukulasuriya K L, Hoffmann J, Di Bisceglie A M.
Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy:
a 5-year follow-up of 150 patients.
Hepatology.
2009;
49(3)
729-738
- 42
Imai Y, Kawata S, Tamura S Osaka Hepatocellular Carcinoma Prevention Study Group et
al.
Relation of interferon therapy and hepatocellular carcinoma in patients with chronic
hepatitis C.
Ann Intern Med.
1998;
129(2)
94-99
- 43
Kasahara A, Hayashi N, Mochizuki K Osaka Liver Disease Study Group et al.
Risk factors for hepatocellular carcinoma and its incidence after interferon treatment
in patients with chronic hepatitis C.
Hepatology.
1998;
27(5)
1394-1402
- 44
International Interferon-alpha Hepatocellular Carcinoma Study Group .
Effect of interferon-alpha on progression of cirrhosis to hepatocellular carcinoma:
a retrospective cohort study.
Lancet.
1998;
351(9115)
1535-1539
- 45
Okanoue T, Itoh Y, Minami M Viral Hepatitis Therapy Study Group et al.
Interferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic
hepatitis C but not significantly in an advanced stage: a retrospective study in 1148
patients.
J Hepatol.
1999;
30(4)
653-659
- 46
Cammà C, Giunta M, Andreone P, Craxì A.
Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based
approach.
J Hepatol.
2001;
34(4)
593-602
- 47
Di Bisceglie A M, Shiffman M L, Everson G T HALT-C Trial Investigators et al.
Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon.
N Engl J Med.
2008;
359(23)
2429-2441
- 48
Sulkowski M S, Mehta S H, Torbenson M S et al..
Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults.
AIDS.
2007;
21(16)
2209-2216
- 49
Graham C S, Baden L R, Yu E et al..
Influence of human immunodeficiency virus infection on the course of hepatitis C virus
infection: a meta-analysis.
Clin Infect Dis.
2001;
33(4)
562-569
- 50
Fong T L, Valinluck B, Govindarajan S, Charboneau F, Adkins R H, Redeker A G.
Short-term prednisone therapy affects aminotransferase activity and hepatitis C virus
RNA levels in chronic hepatitis C.
Gastroenterology.
1994;
107(1)
196-199
- 51
Henry S D, Metselaar H J, Van Dijck J, Tilanus H W, Van Der Laan L J.
Impact of steroids on hepatitis C virus replication in vivo and in vitro.
Ann N Y Acad Sci.
2007;
1110
439-447
- 52
Magrin S, Craxi A, Fabiano C et al..
Hepatitis C viremia in chronic liver disease: relationship to interferon-alpha or
corticosteroid treatment.
Hepatology.
1994;
19(2)
273-279
- 53
Calleja J L, Albillos A, Cacho G, Iborra J, Abreu L, Escartín P.
Interferon and prednisone therapy in chronic hepatitis C with non-organ-specific antibodies.
J Hepatol.
1996;
24(3)
308-312
- 54
Bahra M, Neumann U P, Jacob D, Langrehr J M, Neuhaus P.
Repeated steroid pulse therapies in HCV-positive liver recipients: significant risk
factor for HCV-related graft loss.
Transplant Proc.
2005;
37(4)
1700-1702
- 55
Berenguer M, Aguilera V, Prieto M et al..
Significant improvement in the outcome of HCV-infected transplant recipients by avoiding
rapid steroid tapering and potent induction immunosuppression.
J Hepatol.
2006;
44(4)
717-722
- 56
Berenguer M, Ferrell L, Watson J et al..
HCV-related fibrosis progression following liver transplantation: increase in recent
years.
J Hepatol.
2000;
32(4)
673-684
- 57
Neumann U P, Berg T, Bahra M et al..
Long-term outcome of liver transplants for chronic hepatitis C: a 10-year follow-up.
Transplantation.
2004;
77(2)
226-231
Paul D BerkM.D.
Professor of Medicine, Columbia University Medical Center, Division of Digestive and
Liver Diseases, William Black Medical Research Building
Room 1002, 650 West 168th Street, New York, NY 10032
eMail: pb2158@columbia.edu
